Abstract-A missense variant (R83H) of the gene (KCNE3) encoding a potassium channel-associated peptide, MinKrelated peptide 2 (MiRP2), has been reported in periodic paralysis patients. In the current study, no difference in the frequency of the MiRP2-R83H variant between periodic paralysis patients and healthy individuals was found. Furthermore, there was no segregation of this gene variant with the disease. These observations weaken the proposal that MiRP2-R83H causes periodic paralysis. NEUROLOGY 2003;61:857-859 Periodic paralyses are disorders of the skeletal muscle characterized by episodic attacks of muscle weakness caused by abnormal membrane excitability.
1,2
They are classified as hyperkalemic (hyperPP) or hypokalemic (hypoPP) periodic paralysis according to variations in blood potassium levels during the attacks. Both sporadic and genetic forms of these diseases have been described. The better-characterized sporadic form is hypoPP with thyrotoxicosis, which is more prevalent in people of Asian descent. The recognized genetic forms of periodic paralysis are autosomal dominant. Most dominant hyperPP cases are caused by missense mutations in the SCN4A skeletal muscle voltage-gated sodium channel gene, whereas most hypoPP cases are due to missense mutations in CACNA1S skeletal muscle voltage-gated L-type calcium channel gene (hypoPP1; approximately 70% of the cases) or in SCN4A gene (hypoPP2; approximately 10% of the cases). 3 The SCN4A mutations associated with hyperPP or hypoPP are distinct and induce different biophysical defects of the voltagegated sodium channel. Andersen's syndrome is another form of dominant periodic paralysis associated with cardiac and dysmorphic signs and is due to missense or in-frame deletions of the KCNJ2 inwardly rectifying potassium channel gene. 4 A missense variant in the KCNE3 gene encoding MinK-related peptide 2 (MiRP2), a potassium channel-associated peptide, was reported in 2 of 100 independent cases with periodic paralysis. 5 A transition from G to A was identified at position 340 of KCNE3 mRNA, predicting an arginine-to-histidine amino acid substitution at position 83 of MiRP2 peptide (MiRP2-R83H variant). The variant segregated with the disease in two small pedigrees and was absent from 120 control subjects. In a distinct study, 1 patient of 15 with thyrotoxic hypoPP carried the MiRP2-R83H variant. 6 These reports suggested that the MiRP2-R83H variant caused hereditary periodic paralyses and predisposed to thyrotoxic hypoPP. Following up these observations, we studied the frequency of the MiRP2-R83H variant in patients with periodic paralysis and in a large group of 506 healthy control subjects. We also analyzed the segregation of this variant with the disease.
Patients and methods.
We investigated a total of 104 patients (Group 1) for whom the diagnosis of periodic paralysis was established. Based on clinical and genetic analyses, we could divide this group of patients into two subgroups: A and B. Subgroup A consisted of 64 probands with either hypoPP or hyperPP who were unsuccessfully screened for mutations in SCN4A and CACNA1S genes. It is worth noting that seven of these patients had hypoPP with thyrotoxicosis. Subgroup B comprised 40 hypoPP patients with identified mutations in SCN4A (R669H, n ϭ 1; R672H, n ϭ 7; R672G, n ϭ 1; R672S, n ϭ 1) or CACNA1S (R528H, n ϭ 23; R1239H, n ϭ 7). The control group (Group 2) consisted of 506 healthy individuals.
DNA was extracted from blood samples obtained after informed consent of each individual according to European Union and French bioethics laws. PCR amplification of the DNA fragment encompassing site 340 of the KCNE3 gene was performed as described.
3 DNA fragments were analyzed using single-strand conformation polymorphism analysis (SSCP) denaturing highpressure liquid chromatography (DHPLC). The SSCP screening procedure included a denaturation step and migration at 7°C. The DHPLC was performed on a DHPLC WAVE 2100A system (Transgenomic, Omaha, NE). Abnormal DNA products were further characterized by direct sequencing following a new PCR amplification.
Results. We estimated the frequency of the MiRP2-R83H variant in a large group of periodic paralysis patients, using SSCP or DHPLC screening techniques. Our results showed that only 1 patient of 104 carried this variant (table), which yields a frequency of 0.0096. This patient belonged to Subgroup B (hypoPP with SCN4A mutations) and carried both MiRP2-R83H variant and SCN4A-R672H mutation, which causes hypoPP2 (figure). Given this result, we screened available members of this family for both MiRP2-R83H and SCN4A-R672H. We found that the affected father carried the SCN4A-R672H mutation, whereas the healthy mother carried the MiRP2-R83H variant (see the figure) . Both father and son presented an unambiguous hypoPP with a decreased blood potassium levels to 2 mM on average during attacks of muscle weakness. It is worth noting that the severity of the disease (duration and frequency of the attacks) was comparable between father (carrying SCN4A-R672H) and son (carrying both SCN4A-R672H and MirP2-R83H). In Subgroup A (hypoPP or hyperPP patients with no SCN4A or CACNA1S mutation), none of the patients presented the MiRP2-R83H variant. In the group of healthy controls (Group 2), 8 of 506 healthy individuals carried the MirP2-R83H, yielding a frequency of 0.0158. Altogether, our data indicate that the frequency of MiRP2-R83H variant obtained in patients with periodic paralysis (0.0096) is not different from that observed in healthy control subjects (0.0158) (see the table).
Discussion. This study demonstrates that the frequency of the MiRP2-R83H variant obtained from patients with periodic paralysis is comparable with that obtained from a large group of healthy control subjects. It is noteworthy that the only patient carrying MiRP2-R83H variant also carried a wellcharacterized hypoPP2 SCN4A mutation. In contrast to MiRP2-R83H variant, this hypoPP2 SCN4A variant clearly segregated with the disease. Altogether, our results argue against a causative role of the MiRP2-R83H variant in periodic paralyses.
In the original report, the MiRP2-R83H variant was associated with either hyperPP-or hypoPP-like phenotypes, 5 which weakens the hypothesized causative link between genotype and phenotype. Indeed, up to now, approximately 30 missense mutations in the SCN4A and 3 in the CACNA1S genes have been described, and none of them has been linked to both phenotypes.
1,2 One may therefore not exclude that, alike our SCN4A-R672H patient, patients reported by Abbott and et al 5 carry, in addition to MiRP2- R83H variant, other distinct hyperPP or hypoPP mutations that remained unidentified despite the efforts of the authors. In the same study, the authors investigated the functional consequences of MiRP2-R83H in heterologous expression systems. 5 They hypothesized that MiRP2 operates with Kv3.4 potassium channels in skeletal muscle to set the resting membrane potential and that MiRP2-R83H variant may alter this function when co-expressed with wild-type MiRP2. However, a further and more direct confirmation of MiRP2 role in skeletal muscle is needed, as conflicting expression data have been reported for KCNE3. 5, 7 MiRP2 may indeed interact with different potassium channel subunits, as it has been suggested for MiRP1 in heart. [8] [9] [10] The in vivo pathophysiologic relevance of the functional abnormalities induced by MiRP2-R83H when coexpressed in vitro with Kv3.4 needs, therefore, further evaluation before this variant can be classified as a risk factor for muscle excitability diseases.
Figure. A family with hypokalemic periodic paralysis (hypoPP2). (A) Pedigree of a hypoPP family (hypoPP2

